Following the advice from the advisory Council on the Misuse of Drugs (ACMD) about the harm associated with Pregabalin and Gabapentin these drugs will, from April 2019, be placed in schedule 3 under the Misuse of Drugs Regulations 2001.
This means that Gabapentin and Pregabalin cannot be supplied via repeat dispensing and prescriptions will only be valid for 28 days of the appropriate prescription date. In addition they will not be available to supply via the Electronic Prescription service (EPS) (until full rollout of controlled drug prescribing via EPS) and they will require the full prescription writing requirements in line with Schedule 2 and 3 drugs.
Although these changes are coming into effect from April 2019, Emis is making the necessary changes in MKB release version 147, which is being rolled out to practices over the following eight weeks to ensure the changes are in place in time for the regulatory changes.
Contractors who have patients regularly taking Gabapentin and Pregabalin formulations will need to be alert to these items disappearing off EPS tokens and the production of an FP10 at the surgery.
Please check the scripts have been received before the patient runs out.
More information about this change can be found in this BRIEFING NOTE.